CNAT now trading as HSTO—following reverse-merger and 1:10 reverse split: https://www.globenewswire.com/news-release/2020/05/27/2039308/0/en/Histogen-Announces-Successful-Completion-of-its-Merger-with-Conatus-Pharmaceuticals.html The company’s lead program is in androgenetic alopecia (#msg-155555588).